Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical pharmacokinetics of sulphasalazine.

Clinical pharmacokinetics - 1 Jan 2000

Das K M, Dubin R

Abstract excerpt

Sulphasalazine consists of 5-aminosalicylic acid and sulphapyridine both linked together by an azo bond. Sulphasalazine is clearly useful in long-term management of ulcerative colitis and may be useful in Crohn's disease. The absorption, metabolism and excretion of sulphasalazine is similar in volunteers and patients with ulcerative colitis or Crohn's disease. Sulphasalazine serves as a vehicle to deliver its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Anti-Bacterial Agents
Share to Binding, Competitive

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Calcium

Share to Kinetics

Share to Phenotype

Share to Protein Binding

Share to Time Factors

Source

Identifiers

PMID: 15752
DOI: 10.2165/00003088-197601060-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical pharmacokinetics of sulphasalazine.PMID 15752Read ↗

Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.Semantic proximity Read ↗

Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.Semantic proximity Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.Semantic proximity Read ↗

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.Semantic proximity Read ↗

Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man.Semantic proximity Read ↗

Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.Semantic proximity Read ↗

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.Semantic proximity Read ↗

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.